Targeted Therapy Treatment Innovations in AML

EP. 1: Role of First Generation FLT3 Inhibitors in AML

August 26th 2021

Expert discusses the role of FLT3 inhibitors in the treatment of AML and if benefit from midostaurin in combination with chemotherapy can be predicted.

EP. 2: Role of Second Generation FLT3 Inhibitors in AML

August 26th 2021

Expert examines the status of second-generation FLT3 inhibitors in newly diagnosed AML patients and the challenge with comparing clinical trial efficacy endpoints.

EP. 3: Part 1: IDH1 & IDH2 Inhibitors In Newly Diagnosed AML

August 26th 2021

Alexandra S. Wolff, PharmD, BCOP, discusses use of IDH1 and IDH2 inhibitors in newly diagnosed AML patients and highlights recently released trial data.

EP. 4: Part 2: IDH1 & IDH2 Inhibitors In Newly Diagnosed AML

August 26th 2021

Expert continues discussion of IDH1 and IDH2 inhibitors in AML and examines prioritization of IDH1 and IDH2 inhibitors versus venetoclax in newly diagnosed AML.

EP. 5: Role of Venetoclax in Treatment of AML

August 26th 2021

Expert discusses the role of venetoclax in the treatment of AML and if achievement of MRD negativity can be used to predict long-term outcomes.

EP. 6: Part 1: Practical Considerations For Venetoclax in AML

August 26th 2021

Alexandra S. Wolff, PharmD, BCOP, highlights considerations for optimal use of venetoclax in patients with AML, such as tumor lysis syndrome prophylaxis.

EP. 7: Part 2: Practical Considerations For Venetoclax in AML

August 26th 2021

Expert continues discussion on important considerations for the optimal use if venetoclax in patients with AML, such as CYP3A4 and p-glycoprotein drug interactions.

EP. 8: 5-Year Follow-Up Data For CPX-351 in AML

August 26th 2021

Alexandra S. Wolff, PharmD, BCOP, explores the 5-year follow-up data from the phase 3 trial of CPX-351 in AML.

EP. 9: CPX-351 in Clinical Practice For AML

August 26th 2021

Alexandra S. Wolff, PharmD, BCOP, comments on her experience with CPX-351 in clinical practice and the potential to combine CPX-351 with targeted agents for AML.